After Tilray released its adjusted EBITDA guidance for 2026, the stock price plummeted nearly 20%.

In early trading on Tuesday Eastern Time, Canadian medical cannabis cultivation, processing, and distribution company Tilray's stock plummeted nearly 20% at one point, after the company announced adjusted EBITDA guidance for 2026, expecting to reach $62-72 million. This forecast is based on strong growth in its international cannabis business and strategic adjustments in its beverage business segment. The company's international cannabis division achieved record high revenue and maintained a leading position in several product categories in Canada. The strategic transformation of the beverage division is expected to bring significant cost savings.